Colombia’s Instituto Nacional De Cancerologia Chooses IntraOp’s Mobetron to Help Fight Cancer
IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, announced today that it has received an order for the Mobetron from the Instituto Nacional de Cancerologia, in Bogota, Colombia. This will mark the first Mobetron in Latin America, as well as the first OR-ready radiation device in South America. IntraOp’s Mobetron is a mobile electron beam radiation device that applies a direct application of intraoperative electron-beam radiation therapy (IOERT) to a tumor during cancer surgery.
Instituto Nacional de Cancerologia is a leading public institution with more than 70 years of experience with many diverse oncological diseases. Innovators in the treatment of cancer, the Instituto Nacional de Cancerologia has helped implement techniques for minimally invasive surgery for cancer and other diseases. Their Pediatric Oncology Group is a leader in Colombia and one of the most highly recognized in Latin America.
The Mobetron enables radiation and surgical oncologists to target the exact area that requires radiation and to deliver high doses of radiation directly to the affected tissue during the cancer surgery. Since the Mobetron is a mobile, self-shielding device, the hospital can move the Mobetron between operating rooms with ease, avoiding the high cost of outfitting radiation rooms to accommodate traditional devices. Key benefits include: better local tumor control, increased survival rates, shorter treatment cycles and fewer side effects.
Chief Scientist of IntraOp, Don Goer, said, “We are very pleased that the Instituto Nacional de Cancerologia has chosen the Mobetron to be part of their comprehensive cancer treatment program. It is an honor for IntraOp to be part of such an innovative facility and we look forward to working with them to extend IOERT to other countries in the region.”
About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively — for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
For more information about IntraOp Medical and the Mobetron, please visit: www.intraopmedical.com
For more information about Instituto Nacional de Cancerologia, please visit: www.incancerologia.gov.co
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company’s products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.